Prospective
The APL Paradigm and the “Co-Clinical Trial” Project...........108
C. Nardella, A. Lunardi, A. Patnaik, L. C. Cantley, and P. P. Pandolfi

REVIEW
The Drug-Induced Degradation of Oncoproteins: An Unexpected Achilles' Heel of Cancer Cells?..............117
J. Ablain, R. Nasr, A. Bazarbachi, and H. de Thé

Temporal Dissection of Tumorigenesis in Primary Cancers..............137
S. Durinck, C. Ho, N. J. Wang, W. Liao, L. R. Jakkula, E. A. Collisson, J. Pons, S-W. Hong, S-W. Hsu, N. Huh, I. M. Neuhaus, S. Herrero-González, and A. Di Cristofano

RESEARCH WATCH
Selected highlights of recent articles of exceptional significance from the cancer literature..............96

IN THIS ISSUE
Highlighted research articles..........................x

NEWS IN BRIEF
Important news stories affecting the community......................92

NEWS IN DEPTH
Drug Discovery Gets an Academic Push ......................93

IN THE SPOTLIGHT
New Insight Puts CRAF in Sight as a Therapeutic Target.........98
A. P. Rebocho and R. Marais

Commentary on Karreth et al., p. 128

The First Line of Intra-abdominal Metastatic Attack: Breaching the Mesothelial Cell Layer...........100

Commentary on Iwanicki et al., p. 144

Kras, Pten, NF-κB, and Inflammation: Dangerous Liaisons...........103
P. J. Chiao and J. Ling

Commentary on Ying et al., p. 158

New Routes to Old Places: PIK3R1 and PIK3R2 Join PIK3CA and PTEN as Endometrial Cancer Genes..................................106
S. Herrero-González and A. Di Cristofano

Commentary on Cheung et al., p. 170

C-Raf Is Required for the Initiation of Lung Cancer by K-RasG12D...........128
F. A. Karreth, K. K. Frese, G. M. DeNicola, M. Baccarini, and D. A. Tuveson

Précis: C-Raf, but not B-Raf, is required for K-RasG12D–induced tumorigenesis and should be considered an important therapeutic target.

Temporal Dissection of Tumorigenesis in Primary Cancers..............137

Précis: Next-generation sequencing is used to temporally order the occurrence of genetic aberrations in epithelial cancer.
Ovarian Cancer Spheroids Use Myosin-Generated Force to Clear the Mesothelium

M. P. Iwanicki, R. A. Davidowitz, M. R. Ng, A. Besser, T. Muranen, M. Merritt, G. Danuser, T. Ince, and J. S. Brugge

Précis: Time-lapse video microscopy shows that ovarian cancer spheroids clear the mesothelium via myosin-generated force.

PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-κB–Cytokine Network


Précis: PTEN is shown to be a tumor suppressor in human PDAC and controls NF-κB–dependent transcription via PI3K-AKT signaling.

RESEARCH ARTICLES

Cheung and colleagues report aberrations in the PI3K pathway occur in a majority of endometrioid endometrial cancers, with coordinate mutations of multiple pathway members being more common than predicted by chance. Multiple gain-of-function \textit{PIK3R1} and \textit{PIK3R2} mutations result in the stabilization of PTEN protein with likely contribution from the ubiquitin-proteasome degradative pathway, as depicted by the cover. For details, please see the article by Cheung and colleagues on page 158.

ON THE COVER

Cheung and colleagues report aberrations in the PI3K pathway occur in a majority of endometrioid endometrial cancers, with coordinate mutations of multiple pathway members being more common than predicted by chance. Multiple gain-of-function \textit{PIK3R1} and \textit{PIK3R2} mutations result in the stabilization of PTEN protein with likely contribution from the ubiquitin-proteasome degradative pathway, as depicted by the cover. For details, please see the article by Cheung and colleagues on page 158.